NT
Nutshell Therapeutics at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
Nutshell Therapeutics brings 2 presentations to ENA 2026 in Barcelona. Its posters centre on small molecules aimed at the RAS pathway and mutant p53. They cover NTS242, a covalent PI3Kα-RAS disruptor with an AI-generated scaffold, and a preclinical combination of NTS071 with venetoclax in TP53 Y220C-mutated acute myeloid leukemia.
| Organization | ENA 2026 Attendance |
|---|---|
NT Nutshell Therapeutics Shanghai, China | |
Clinical-stage biotech developing allosteric small molecules, including NTS071 for TP53 Y220C-mutant tumours. | Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm |
Find decision makers at Nutshell Therapeutics
Tell us what you sell and we’ll find the people at Nutshell Therapeutics most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction